{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123727","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.545009+00:00","generated_at":"2026-05-30T02:55:04.995596+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sana Biotechnology Q3 2024 net loss $59.9M; advancing three clinical programs; cash runway into 2026","bullets":["Net loss of $59.9M ($0.25/sh) for Q3 2024 vs net income of $1.0M in Q3 2023.","Cash and equivalents $199.0M as of Sep 30, 2024; expected cash runway into 2026.","Appointed Dhaval Patel as Chief Scientific Officer; expanding focus on type 1 diabetes and B-cell autoimmune diseases.","Enrolling patients in three studies: UP421 (type 1 diabetes), GLEAM (SC291 autoimmune), VIVID (SC262 oncology); data expected in 2024/2025.","Non-GAAP operating cash burn $153.1M for first nine months 2024; strategic repositioning may increase 2024 burn above prior guidance of <$200M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123727","json":"https://secwatch.observer/filing/0000950170-24-123727.json","markdown":"https://secwatch.observer/filing/0000950170-24-123727.md","text":"https://secwatch.observer/filing/0000950170-24-123727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/0000950170-24-123727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024123727/sana-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:55:04.995596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}